Cargando…
Biosimilars in Pediatric IBD: Updated Considerations for Disease Management
Biologic drugs have significantly modified the pharmacological management of several chronic conditions, including inflammatory bowel diseases (IBD). By contrast, in the last two decades, biologics have been associated with increased direct medical costs. As patents for the reference drugs have expi...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9205321/ https://www.ncbi.nlm.nih.gov/pubmed/35721798 http://dx.doi.org/10.2147/BTT.S367032 |